As the world continues to battle the pandemic of SARS Covid-19, SG Biotech has implemented business continuity plans both in Switzerland and Russia to ensure that we maintain the supply of our important hemophilia treatments. We do so by implementing measures which, at once maximize the safety of our employees, but also secure supply without interruption. We wish everybody a safe and healthy outcome from this threat and look forward to when our lives can resume a normality which we can never again take for granted.